Gut microbiome and NAFLD: impact and therapeutic potential

Area of Science:

• Gastroenterology and Hepatology
• Microbiology
• Immunology

Background:

• Non-Alcoholic Fatty Liver Disease (NAFLD) affects over 30% of the global population, representing a significant health burden.
• The gut microbiota, encompassing bacteria, viruses, fungi, and parasites, is increasingly recognized for its role in NAFLD pathogenesis.
• Dysbiosis in gut microbial communities contributes to liver fat accumulation and inflammation.

Purpose of the Study:

• To review the current understanding of gut microbiota composition and function in NAFLD.
• To explore the impact of bacteria, viruses, fungi, and parasites on NAFLD development and progression.
• To discuss potential therapeutic interventions targeting the gut microbiota for NAFLD management.

Main Methods:

• Literature review synthesizing current research on gut microbiota and NAFLD.
• Analysis of studies investigating bacterial dysbiosis, viral influences, fungal associations (e.g., Candida), and parasitic exposure (hygiene hypothesis).
• Examination of therapeutic strategies including probiotics, prebiotics, and fecal microbiota transplantation.

Main Results:

• Gut bacterial dysbiosis alters pathways leading to liver fat accumulation and inflammation.
• The gut virome influences microbial dynamics and host metabolism.
• Specific fungi like Candida are detrimentally associated with NAFLD markers, while reduced parasite exposure may impact immune and metabolic regulation.

Conclusions:

• The gut microbiota plays a multifaceted role in NAFLD.
• Interventions targeting the gut microbiota hold therapeutic promise for NAFLD.
• Comprehensive NAFLD management strategies must consider the complex interactions within the gut microbial ecosystem.